Intercontinental collaboration in clinical trials for children and adolescents with cancer-A systematic review by ACCELERATE.
adolescent cancer
childhood cancer
clinical research
clinical trials
drug development
international collaboration
rare diseases
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
21
09
2021
received:
11
08
2021
accepted:
21
09
2021
pubmed:
24
10
2021
medline:
23
3
2022
entrez:
23
10
2021
Statut:
ppublish
Résumé
Since pediatric cancer drug development is a global enterprise, we sought to provide an overview of the landscape of intercontinental clinical trials in pediatric oncology opened over the last decade. ClinicalTrials.gov was systematically searched to identify all clinical therapeutic trials which opened between 2010 and 2020 and recruited pediatric patients (<18 years) with cancer. Over the last 10 years, 295 (8.7%) of 3383 therapeutic pediatric cancer trials were international and 182 (5.4%) were intercontinental. Most intercontinental trials were phase-1 or 2, with 25% late-phase, 65% were sponsored by industry, and North America was involved in 92%. Industry-sponsored proportionally more phase-1 trials than academia (41% vs. 25%); conversely, academia sponsored more phase-2 and late-phase trials (39% and 31% vs. 36% and 21%, respectively) (p = 0.020). North America-Europe collaboration was predominantly industry sponsored as opposed to North America-Oceania and Europe-Oceania collaboration, more frequently academic (p < 0.0001). Most late-phase trials (18/20, 90%) focusing on pediatric malignancies were conducted by academic sponsors and 10 of these were conducted by Children's Oncology Group (COG)/National Cancer Institute in the United States and Oceania. There was no significant increase over time of intercontinental trials and a trend for a reduction in academic trials. Despite the relative rarity of childhood malignancies, especially within molecular subtypes, only 5.4% of pediatric cancer trials were intercontinental. The number of intercontinental trials remains small, with no significant increase over the last decade. The ACCELERATE International Collaboration Working Group aims to identify existing hurdles and propose solutions to improve intercontinental collaboration in clinical research for the benefit of children and adolescents with cancer.
Sections du résumé
BACKGROUND
Since pediatric cancer drug development is a global enterprise, we sought to provide an overview of the landscape of intercontinental clinical trials in pediatric oncology opened over the last decade.
METHODS
ClinicalTrials.gov was systematically searched to identify all clinical therapeutic trials which opened between 2010 and 2020 and recruited pediatric patients (<18 years) with cancer.
RESULTS
Over the last 10 years, 295 (8.7%) of 3383 therapeutic pediatric cancer trials were international and 182 (5.4%) were intercontinental. Most intercontinental trials were phase-1 or 2, with 25% late-phase, 65% were sponsored by industry, and North America was involved in 92%. Industry-sponsored proportionally more phase-1 trials than academia (41% vs. 25%); conversely, academia sponsored more phase-2 and late-phase trials (39% and 31% vs. 36% and 21%, respectively) (p = 0.020). North America-Europe collaboration was predominantly industry sponsored as opposed to North America-Oceania and Europe-Oceania collaboration, more frequently academic (p < 0.0001). Most late-phase trials (18/20, 90%) focusing on pediatric malignancies were conducted by academic sponsors and 10 of these were conducted by Children's Oncology Group (COG)/National Cancer Institute in the United States and Oceania. There was no significant increase over time of intercontinental trials and a trend for a reduction in academic trials.
CONCLUSIONS
Despite the relative rarity of childhood malignancies, especially within molecular subtypes, only 5.4% of pediatric cancer trials were intercontinental. The number of intercontinental trials remains small, with no significant increase over the last decade. The ACCELERATE International Collaboration Working Group aims to identify existing hurdles and propose solutions to improve intercontinental collaboration in clinical research for the benefit of children and adolescents with cancer.
Identifiants
pubmed: 34687165
doi: 10.1002/cam4.4356
pmc: PMC8633236
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
8462-8474Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Cancer Med. 2021 Dec;10(23):8462-8474
pubmed: 34687165
Lancet Oncol. 2013 Mar;14(3):e95-e103
pubmed: 23434338
N Engl J Med. 2004 Sep 16;351(12):1250-1
pubmed: 15356289
Lancet Oncol. 2013 Mar;14(3):e117-24
pubmed: 23434337
Lancet Oncol. 2016 Oct;17(10):1396-1408
pubmed: 27569442
Eur J Cancer. 2015 Jan;51(2):218-24
pubmed: 25434924
BMJ. 2018 May 25;361:k1452
pubmed: 29802130
Ther Innov Regul Sci. 2019 Sep;53(5):639-640
pubmed: 30411627
Cell. 2016 Feb 25;164(5):1060-1072
pubmed: 26919435
Lancet Oncol. 2018 May;19(5):705-714
pubmed: 29606586
N Engl J Med. 2020 Jun 4;382(23):2207-2219
pubmed: 32492302
Lancet Oncol. 2013 Mar;14(3):e125-35
pubmed: 23434339
Lancet Oncol. 2016 Jul;17(7):896-906
pubmed: 27237614
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
JCO Glob Oncol. 2020 Aug;6:1264-1275
pubmed: 32762563
J Clin Oncol. 2020 Dec 20;38(36):4227-4230
pubmed: 32946356
Lancet Oncol. 2014 Jan;15(1):35-47
pubmed: 24314616
Nat Rev Clin Oncol. 2017 Aug;14(8):497-507
pubmed: 28508875
JCO Glob Oncol. 2020 Feb;6:9-18
pubmed: 32031437